RxDoctor Payments DataLook up a doctor →

Charles Moore, MD

Cardiovascular Disease · Birmingham, ALNPI 1699795641

Payments from drug & device makers

$171,560in general payments, 2019–2025

Across 415 payments — averaging $413.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$118K
  • Pfizer$40K
  • Sanofi US Services Inc.$7K
  • Abiomed$2K
  • Novartis$516
  • Johnson & Johnson$473
  • plus $4K from 30 others

What the payments were for

  • Speaking & faculty fees$36,85078%
  • Travel & lodging$2,0024%
  • Food & beverage$8,28018%
  • Education$1380%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$171,560 in reported general payments places this provider in the 90th percentile of 292 cardiovascular disease providers in Alabama.

See all cardiovascular disease providers in Alabama

Medicare billing

Part B allowed, 2024
$59,288
Medicare patients
879
Services billed
1,641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis39$846,162
EntrestoSacubitril/Valsartan219$176,139
LetairisAmbrisentan13$165,694
FarxigaDapagliflozin Propanediol90$66,937
JardianceEmpagliflozin77$58,419
EliquisApixaban49$39,370
VerquvoVericiguat29$20,824
Tacrolimus57$15,490
TrulicityDulaglutide11$10,879
Tadalafil16$4,968
Spironolactone231$2,358
Mycophenolate Mofetil15$1,390
Bumetanide25$1,376
Eplerenone17$1,241
Digoxin68$1,144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$40,469$885,53388 claims
NovartisEntresto$516$176,139219 claims
GileadLetairis$108$165,69413 claims
AstraZenecaFarxiga$162$66,93790 claims
Boehringer IngelheimJardiance$400$58,41977 claims
MerckVerquvo$261$20,82429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 cardiovascular disease providers in Alabama.

Other cardiovascular disease in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →